Observational studyAdvances in therapy2025

Real-World Effectiveness and Safety of Infliximab Biosimilar CT-P13 for Rheumatic Diseases: A National Observational Cohort Study (ReFLECT).

Hubert Marotte et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.